Addressing urgent unmet needs in rare diseases
At Hansa Biopharma, we are on a mission to develop innovative immunomodulatory treatments and bring them to those patients whose medical needs have been overlooked.
This is Hansa“We are leveraging our cutting-edge science to develop lifesaving and life altering therapies for patients with rare immunological conditions.”
Søren Tulstrup, President and CEO
15
Years of innovation
10
Clinical and preclinical programs
+30
Nationalities represented in our workforce
Our Technology platform
Our unique antibody-cleaving enzyme technology
We have developed our proprietary antibody-cleaving enzyme technology platform to target pathogenic or disease causing antibodies. Our first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate IgG antibodies in the plasma and tissue through a single intravenous treatment. We are currently investigating the use of this molecule for treating and preventing rare conditions caused by IgG antibodies in the acute phase, within transplantation, autoimmunity, gene therapy and oncology.
Hansa story
Empowering rare
At Hansa, our ambition is to help empower patients with rare immunological conditions to live long and healthy lives. By developing innovative, lifesaving and life altering treatments and bringing them from the laboratory to the bedside of the patient, we strive to help address their unmet medical need.
Media
Our latest press releases
The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma’s Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
Regulatory press release
12/09/2022
Hansa Biopharma: Issue and repurchase of class C shares for incentive programs
Regulatory press release
09/09/2022
Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix® in highly sensitized kidney transplant patients
22/08/2022
European Society for Organ Transplantation’s (ESOT) guidelines for desensitization treatment of highly sensitized kidney transplant patients published in Transplant International
10/08/2022
Therapeutic Areas
Our unique enzyme technology has the potential to transform the lives of people affected by rare immunologic conditions, including transplant rejection, genetic diseases, autoimmune conditions, and cancer.
Melissa. Highly sensitized kidney patient on dialysis, USA.
Sustainability
We are the bigger picture
Since 2007, we have been fully committed to those living with rare conditions and have worked to develop lifesaving and life altering therapies through pioneering research and innovation. We strive to live up to the high ethical standards we set for ourselves, and to be a force for good both for individuals and society as a whole.
Our commitmentMedia
News and insights
Patient stories
Life on tour with chronic kidney disease
“I had always played the guitar and wrote songs but never really did anything with it. Nothing was going to hold me back now! No more excuses… there wasn’t time!”
Patient stories
Taking care of a transplanted kidney through physical and mental health
“And people say to me: I never would have guessed that you had a kidney transplant… when I hear those words, they keep me motivated, and keep me going.”
Employee stories
Working in an epicentre of pioneering innovation
“The key to our collective success at Hansa Biopharma goes far beyond our scientific breakthroughs, as it stems from the amazing team spirit we have built.”
Patient stories
Suspended time: a journey from diagnosis to transplant
"Dialysis may sound simple, but it isn’t, and over the course of his treatment Ron underwent several different kinds, all of which made him feel awful."
Meetings of interest
Impactful interaction with the scientific and medical community
At Hansa, we are focused on the bigger picture and want help rare disease patients live long and healthy lives. We do this also by constant engagement with the scientific and healthcare communities. We use this opportunity to not only raise awareness about the unmet needs of the patients, but also to help advance the understanding in these complex fields. Meetings of interestReady for a new career? Join us
